AI Drug Repurposing Helps Find Medicine for Rare Disease
After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a ...
3 Generic Drug Stocks to Watch
The main focus in Teva’s innovative portfolio continues to be neuroscience and immunology, with clinical trials for three key assets underway: olanzapine for treatment of schizophrenia, ...
Terminally ill man 'cured' of immune illness by AI technology
The patient has iMCD, which has a poor survival rate and few treatment options but an AI tool searched through 4,000 ...
AZoAI on MSN13h
AI Predicts Life-Saving Drug for Rare Disease, Patient Enters Remission
Researchers used an AI-driven approach to identify adalimumab as a potential life-saving treatment for idiopathic ...
manilatimes39m
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: ...
manilatimes22h
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...
centerforbiosimilars15h
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast ...